- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
Cell Identity and Spatial Distribution of PD‐1/PD‐L1 Blockade Responders ; day:09 ; month:09 ; year:2024 ; extent:23
Advanced science ; (09.09.2024) (gesamt 23)
- Urheber
-
Li, Xintong
Liu, Yuanxin
Gui, Jun
Gan, Lu
Xue, Jianxin
- DOI
-
10.1002/advs.202400702
- URN
-
urn:nbn:de:101:1-2409091515152.118920255809
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 15.08.2025, 05:32 UTC
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Li, Xintong
- Liu, Yuanxin
- Gui, Jun
- Gan, Lu
- Xue, Jianxin
Ähnliche Objekte (12)
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?
PD-1/PD-L1 blockade in cancer treatment: perspectives and issues
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
PD-L1 blockade immunotherapy rewires cancer-induced emergency myelopoiesis
Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
Optimal Timing of PD-1/PD-L1 Blockade Protects Organ Function During Sepsis
Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway
Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer
Regulatory mechanisms of PD-1/PD-L1 in cancers
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?
PD-1/PD-L1 blockade in cancer treatment: perspectives and issues
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
PD-L1 blockade immunotherapy rewires cancer-induced emergency myelopoiesis
Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
Optimal Timing of PD-1/PD-L1 Blockade Protects Organ Function During Sepsis
Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway
Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer
Regulatory mechanisms of PD-1/PD-L1 in cancers
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?
PD-1/PD-L1 blockade in cancer treatment: perspectives and issues
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
PD-L1 blockade immunotherapy rewires cancer-induced emergency myelopoiesis
Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
Optimal Timing of PD-1/PD-L1 Blockade Protects Organ Function During Sepsis
Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway
Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer